This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Putting a Value on Provenge

Applying this 65% to the total AIPrC patient pool gets me to a total number of eligible Provenge patients. I estimate that number to be 49,823 in 2007, growing to 61,930 in 2012.

Marketing a new drug is not like turning on a light in a darkened room -- results aren't immediate, and not every eligible patient will take a drug, for a variety of reasons. Again, calculating a penetration rate, or market share, is a mix of art and science. In the real world, the best drug with the best marketing will likely top out at 80% market share.

In this case, I start Provenge at a 2% market share because approval, if it happens at all, would come late in 2007. This is a new kind of therapy for cancer and until additional clinical data is gathered and disseminated, I think some doctors might be reluctant to try it. For these reasons, I have peak market share topping out at 55%. I hate to repeat myself, but this is fairly conservative modeling.

In my model, then, I assume 996 Provenge patients in 2007, growing to 34,062 patients in 2012.

Product Pricing

Next consideration is pricing. Dendreon hasn't publicly discussed its thinking on Provenge pricing, but various analysts and commentators have pegged the price in the range of $20,000 to $45,000 a year. I'm using a $30,000 annual price (with a 4% hike per year) in my model, which is in line with other targeted cancer therapies.

That gets us to the end: My 2007 Provenge sales estimate is just under $30 million, rising to $1.24 billion in 2012.

Now, at the top I said my peak sales forecast for Provenge was $1 billion. The lower, final estimate results from the average of three revenue models, each looking at the Provenge market in a slightly different way. I don't always build multiple sales models, but in this case -- given all the unknown variables -- I thought it prudent.

Here's model No. 2:

Prostate cancer - Revenue Model 2
2006 2007 2008 2009 2010 2011 2012
Stage III 24,213 24,939 25,688 26,458 27,252 28,070 28,912
Stage IV 35,749 36,821 37,9268 39,064 40,236 41,443 42,686
% patients failing hormone Tx 85% 85% 85% 85% 85% 85% 85%
Total AIPrC patients 50,968 52,497 54,072 55,694 57,365 59,086 60,858
% patients choosing immunoTx 65% 65% 68% 70% 72% 75% 75%
Eligible Provenge patients 33,129 34,123 36,769 38,986 41,303 44,314 45,644
Provenge penetration 0% 2% 10% 20% 40% 50% 55%
Provenge patients 0 682 3,677 7,797 16,521 22,157 25,104
Cost/year $0 $30,000 $31,200 $32,448 $33,746 $35,096 $36,500
Provenge sales $0 $20,473,725 $114,718,376 $253,001,257 $557,516,461 $777,619,314 $916,284,390

In this model, I start with the number of prostate cancer patients diagnosed with Stage III and Stage IV disease. These numbers aren't easy to find, but are derived from database estimates collected by the National Cancer Institute. These patients more closely represent likely Provenge patients because their disease is more advanced at the time of diagnosis.

I assume that 85% of these patients fail hormone therapy, which makes them eligible for Provenge, based on its likely initial approval. In this model, then, my "total AIPrC patient" estimate is lower than in model No. 1.

After that lower patient base, everything else in the model remains the same. At the end, I derive an estimated U.S. 2007 Provenge sales of $20.5 million, rising to $916.3 million in 2012.

Lastly, let's look at my third model:

Prostate cancer - Revenue Model 3
2006 2007 2008 2009 2010 2011 2012
Annual prostate cancer deaths 27,000 27,540 28,091 28,653 29,226 29,810 30,406
% patients choosing immunoTx 0% 25% 50% 65% 75% 80% 90%
Eligible Provenge patients 0 6,885 14, 045 18,624 21,919 23,848 27,366
Provenge penetration 0% 25% 40% 50% 60% 75% 85%
Provenge patients 0 1721 5618 9312 13,152 17,886 23,261
Cost/year n/a $30,000 $31,200 $32,448 $33,746 $35,096 $36,500
Provenge sales $0 $51,637,500 $175,286,592 $302,159,027 $443,811,179 $627,726,532 $849,012,689

This model is the most conservative because it starts with only the number of prostate cancer patients who die each year, as estimated by the American Cancer Society. This is a much sicker and narrower patient population than will likely receive Provenge, but it does provide a minimum revenue floor for modeling purposes, which is why I like it.

You'll also notice that because this model is based on prostate cancer deaths, I assume a much higher penetration rates for Provenge, maxing out at 85% to 90%. This model comes up with 2007 Provenge revenue of $51.6 million, rising to $850 million in 2012.

When you average all three revenue models together, you get the following Provenge U.S. revenue forecast, with sales topping out at $1 billion:

2007 2008 2009 2010 2011 2012
Average of three models $34,001,575 $151,688,306 $304,628,034 $593,434,528 $825,344,018 $1,002,845,025

In one of my previous Dendreon columns, I said that it was easy to get to peak Provenge sales of $500 million. Obviously, I've easily surpassed that guess with this more rigorous forecast.

Briefly, let me discuss valuation. In the beginning of this article, I peg Dendreon with a $27 share price based on my revenue projections (and assuming, of course, that Provenge is approved.) This valuation underscore why Dendreon, currently at $3.74 and significantly shorted, is a great story to follow.

I derive my valuation using a fairly simple, discounted revenue valuation model. Peak Provenge sales of $1 billion in 2012, risk adjusted by 85% and discounted back just under five years gets to a net present value for Provenge of $355 million. At a reasonable six-times-sales multiple, you get an enterprise value for Dendreon of $2.1 billion. With 82 million shares outstanding and its cash on hand, Dendreon would be worth about $27 per share.

Of course, all these projections are moot if Provenge can't get a positive nod at the FDA advisory panel meeting. We'll see what happens next week.

As originally published, this story contained an error. Please see Corrections and Clarifications .

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DNDN $0.06 -6.02%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs